{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:59Z","timestamp":1791414659423,"version":"4.3.3"},"reference-count":104,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.cardfail.2014.08.004","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T10:33:14Z","timestamp":1408617194000},"page":"841-852","source":"Crossref","is-referenced-by-count":20,"title":["Cardiomyopathy Associated With Cancer Therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Anthony F.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Steingart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2014.08.004_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cardfail.2014.08.004_bib2","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-81-4-475","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.cardfail.2014.08.004_bib5","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cardfail.2014.08.004_bib6","doi-asserted-by":"crossref","first-page":"CD005006","DOI":"10.7326\/0003-4819-88-2-168","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cardfail.2014.08.004_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cardfail.2014.08.004_bib8","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2014.08.004_bib11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib12","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2014.08.004_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cardfail.2014.08.004_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/heart.86.2.219","article-title":"Docetaxel induced cardiotoxicity","volume":"86","author":"Shimoyama","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2014.08.004_bib15","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2014.08.004_bib16","first-page":"827","article-title":"Adriamycin cardiotoxicity: a survey of 1273 patients","volume":"63","author":"Praga","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.cardfail.2014.08.004_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90315-1","article-title":"Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases","volume":"62","author":"von Hoff","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7326\/0003-4819-81-4-475","article-title":"Adriamycin cardiotoxicity in man","volume":"81","author":"Rinehart","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","article-title":"Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization","volume":"88","author":"Bristow","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/ctrv.1999.0128","article-title":"Detection of anthracycline-induced cardiotoxicity","volume":"25","author":"Meinardi","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cardfail.2014.08.004_bib22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib23","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib25","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib26","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: review of potential cardiac problems","volume":"14","author":"Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cardfail.2014.08.004_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cardfail.2014.08.004_bib32","unstructured":"Herceptin [prescribing information]. Available at: http:\/\/www.herceptin.com\/hcp. Accessed November 5, 2013."},{"key":"10.1016\/j.cardfail.2014.08.004_bib33","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.bjc.6603340","article-title":"The evaluation of left ventricular function for patients being considered for, or receiving trastuzumab (Herceptin) therapy","volume":"95","author":"Fox","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cardfail.2014.08.004_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.56.6.1024","article-title":"Analysis of left ventricular function from multiple gated acquisition cardiac blood pool imaging. Comparison to contrast angiography","volume":"56","author":"Burow","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib35","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jacc.2004.05.068","article-title":"Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging","volume":"44","author":"Malm","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/01.CIR.92.4.842","article-title":"Assessment of cardiac function by three-dimensional echocardiography compared with conventional noninvasive methods","volume":"92","author":"Gopal","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib38","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/hrt.73.4.340","article-title":"Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology","volume":"73","author":"Bu'Lock","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.cardfail.2014.08.004_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2143\/AC.63.1.2025328","article-title":"Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines","volume":"63","author":"Radulescu","year":"2008","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1200\/JCO.1984.2.2.112","article-title":"A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin","volume":"2","author":"Ewer","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib42","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2011.06.038","article-title":"Echocardiographic assessment of myocardial strain","volume":"58","author":"Gorcsan","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib43","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1161\/01.CIR.97.19.1970","article-title":"Doppler tissue imaging quantitates regional wall motion during myocardial ischemia and reperfusion","volume":"97","author":"Derumeaux","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib44","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/01.CIR.0000014614.63980.BA","article-title":"Quantification of left ventricular systolic function by tissue Doppler echocardiography: added value of measuring pre- and postejection velocities in ischemic myocardium","volume":"105","author":"Edvardsen","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.echo.2006.08.023","article-title":"Non-Doppler two-dimensional strain imaging by echocardiography\u2014from technical considerations to clinical applications","volume":"20","author":"Perk","year":"2007","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cardfail.2014.08.004_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.echo.2010.02.015","article-title":"Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications","volume":"23","author":"Geyer","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cardfail.2014.08.004_bib47","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2014.08.004_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cardfail.2014.08.004_bib50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/hrt.2009.173997","article-title":"Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study","volume":"96","author":"Ho","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2014.08.004_bib51","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1053\/euhj.2000.2011","article-title":"Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?","volume":"21","author":"Bellenger","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2014.08.004_bib52","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0b013e31829e19be","article-title":"Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy","author":"Lunning","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib54","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer","volume":"8","author":"Lawley","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1532-429X-15-92","article-title":"Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement","volume":"15","author":"Moon","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.cardfail.2014.08.004_bib57","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","article-title":"Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy","volume":"111","author":"Neilan","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib58","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2006.07.003","volume":"48","author":"Hendel","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00432-008-0372-8","article-title":"Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy","volume":"134","author":"Broeyer","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib61","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib62","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib63","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib64","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJMoa0903515","article-title":"Sensitive troponin I assay in early diagnosis of acute myocardial infarction","volume":"361","author":"Keller","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2011.04.007","article-title":"Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome","volume":"162","author":"Weber","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2014.08.004_bib66","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa0900428","article-title":"Early diagnosis of myocardial infarction with sensitive cardiac troponin assays","volume":"361","author":"Reichlin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2014.08.004_bib67","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/hj.1998.v136.89908","article-title":"Elevated B-type natriuretic peptide levels after anthracycline administration","volume":"136","author":"Suzuki","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2014.08.004_bib68","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00392-007-0633-6","article-title":"Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults","volume":"97","author":"Dodos","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejheart.2004.03.009","article-title":"Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction","volume":"7","author":"Daugaard","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2014.08.004_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-012-2039-z","article-title":"High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study","volume":"134","author":"Onitilo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cardfail.2014.08.004_bib71","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib72","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib73","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0140-6736(96)90469-9","article-title":"Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy","volume":"347","author":"Jensen","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2014.08.004_bib75","first-page":"115","article-title":"Beta-blockade in adriamycin-induced cardiomyopathy","volume":"6","author":"Noori","year":"2000","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2014.08.004_bib76","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.healun.2004.12.108","article-title":"Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure","volume":"24","author":"Tallaj","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2014.08.004_bib77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib78","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0002-8703(81)90096-X","article-title":"Dose-effect and structure-function relationships in doxorubicin cardiomyopathy","volume":"102","author":"Bristow","year":"1981","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2014.08.004_bib79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.cardfail.2014.08.004_bib80","first-page":"CD005008","article-title":"Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy","author":"van Dalen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cardfail.2014.08.004_bib81","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(04)01605-5","article-title":"Cardiotoxicity after liposomal anthracyclines","volume":"5","author":"Young","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib82","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(04)01570-0","article-title":"Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin","volume":"5","author":"Jones","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3816\/CGC.2002.n.005","article-title":"Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer","volume":"1","author":"Harris","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.cardfail.2014.08.004_bib84","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib85","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.cardfail.2014.08.004_bib86","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cardfail.2014.08.004_bib87","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib89","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib90","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","article-title":"Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure","volume":"6","author":"Seicean","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2014.08.004_bib91","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1253\/circj.70.321","article-title":"Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria","volume":"70","author":"Kametani","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2014.08.004_bib92","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib93","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib94","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-08-3076","article-title":"Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice","volume":"69","author":"Riad","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.cardfail.2014.08.004_bib95","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib96","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1471-2407-11-318","volume":"11","author":"Pituskin","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cardfail.2014.08.004_bib97","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/bmj.328.7441.711-b","article-title":"Exercise training meta-analysis of trials in patients with chronic heart failure (EXTRAMATCH)","volume":"328","author":"Piepoli","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.cardfail.2014.08.004_bib98","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2009.454","article-title":"Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial","volume":"301","author":"O'Connor","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2014.08.004_bib99","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1161\/01.CIR.98.24.2709","article-title":"Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure","volume":"98","author":"Hambrecht","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cardiores.2006.09.003","article-title":"Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure","volume":"73","author":"Ventura-Clapier","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2014.08.004_bib101","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/CIRCULATIONAHA.111.021774","article-title":"Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms","volume":"124","author":"Scott","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib102","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/01.CIR.0000055013.92097.40","article-title":"Exercise and heart failure: a statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention","volume":"107","author":"Pina","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2014.08.004_bib103","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.fjc.0000199682.43448.2d","article-title":"Exercise training attenuates acute doxorubicin-induced cardiac dysfunction","volume":"47","author":"Chicco","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cardfail.2014.08.004_bib104","doi-asserted-by":"crossref","first-page":"H3254","DOI":"10.1152\/ajpheart.00801.2007","article-title":"Effects of voluntary wheel running on cardiac function and myosin heavy chain in chemically gonadectomized rats","volume":"293","author":"Hydock","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916414011294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916414011294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T04:59:57Z","timestamp":1565758797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916414011294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":104,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1071916414011294"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2014.08.004","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}